1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/45007
Full metadata record
DC FieldValueLanguage
dc.creatorDaniel Silva Moraespt_BR
dc.creatorDeborah de Farias Lelispt_BR
dc.creatorJoão Marcus Oliveira Andradept_BR
dc.creatorLara Meyerpt_BR
dc.creatorAndré Luiz Senna Guimarãespt_BR
dc.creatorAlfredo Maurício Batista de Paulapt_BR
dc.creatorLucyana Conceição Fariaspt_BR
dc.creatorSérgio Henrique Sousa Santospt_BR
dc.date.accessioned2022-09-08T15:56:48Z-
dc.date.available2022-09-08T15:56:48Z-
dc.date.issued2021-02-
dc.citation.volume152pt_BR
dc.citation.spage106501pt_BR
dc.identifier.doihttps://doi.org/10.1016/j.prostaglandins.2020.106501pt_BR
dc.identifier.issn2212-196Xpt_BR
dc.identifier.urihttp://hdl.handle.net/1843/45007-
dc.description.resumoObesity is a chronic disease caused multiple associated factors that results in excessive body fat accumulation. The Renin-Angiotensin System (RAS) unbalance is now recognized as a key factor on regulating body energy and metabolism. Aim: the aim of the present study was to evaluate the Enalapril (ACE inhibitor) effects on the metabolic function and hepatic steatosis of obese mice evaluating Angiotensin Converting Enzymes (ACEs) expression. Methods: the experiment was performed using 32 male Swiss mice (8 weeks old) equally and randomly divided into 4 groups (n = 8): standard diet (ST), standard diet plus Enalapril (ST + ENAL), hyperlipidic diet (HF) and hyperlipidic diet plus Enalapril (HF + ENAL). Weekly measurements of animal weight and feed consumption were performed. At the end of treatment period a glucose tolerance test (GTT) and insulin sensitivity test (IST) were performed. Ultrasonography was used to evaluate hepatic and epididymal fat pad. Liver samples were submitted to HE histology and gene expression analyses were performed using Real-Time PCR. Results: the main results showed a decrease in body weight after treatment with Enalapril, as well as a reduced size of epididymal fat pad (EFP). Hepatic echogenicity and steatosis measurement were lower in the obese groups treated with Enalapril also modulating ACE2/ACE expressions. Conclusions: Enalapril use improved metabolism reducing hepatic steatosis, decreasing ACE expression and increasing ACE2 expression.pt_BR
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológicopt_BR
dc.description.sponsorshipFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Geraispt_BR
dc.description.sponsorshipCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superiorpt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentICA - INSTITUTO DE CIÊNCIAS AGRÁRIASpt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofProstaglandins and Other Lipid Mediatorspt_BR
dc.rightsAcesso Restritopt_BR
dc.subject.otherObesidadept_BR
dc.subject.otherSistema renina-angiotensinapt_BR
dc.subject.otherEsteatose hepáticapt_BR
dc.titleEnalapril improves obesity associated liver injury ameliorating systemic metabolic markers by modulating Angiotensin Converting Enzymes ACE/ACE2 expression in high-fat feed micept_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://www.sciencedirect.com/science/article/pii/S1098882320300940?via%3Dihubpt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
There are no files associated with this item.
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.